Molecular imaging and biology · 2025
Evaluation of [18F]AlF NOTA-5G, an Aluminum [18F]fluoride Labeled Peptide Targeting the Cell Surface Receptor Integrin Alpha(v)beta(6) for PET Imaging.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hausner Sven H, Davis Ryan A, Ganguly Tanushree, Harris Rebecca, Sutcliffe Julie L
Аннотация
PURPOSE: Peptide-based probes targeting integrin αvβ6 have shown promise in clinical trials for cancer imaging based on the high over-expression of this epithelial-specific cell surface receptor in many cancerous tissues. Recently, the αvβ6-targeting gallium-68 labeled DOTA-5G peptide, [68Ga]Ga DOTA-5G, demonstrated diagnostic value in patients with metastatic pancreatic cancer. To facilitate adoption at sites without access to gallium-68 and take advantage of the characteristics of fluorine-18 through convenient [18F]fluoride chelation chemistry, this study evaluated the fluorine-18 labeled analog, [18F]AlF NOTA-5G, in vitro and in vivo in a tumor mouse model, and compared it to [68Ga]Ga DOTA-5G.
PROCEDURES: NOTA-5G was synthesized on solid phase and radiolabeled with aluminum [18F]fluoride to generate [18F]AlF NOTA-5G. Cell binding and internalization of [18F]AlF NOTA-5G were evaluated in paired DX3puroβ6 (αvβ6 +) and DX3puro (αvβ6 -), and pancreatic BxPC-3 (αvβ6 +) cells. Imaging (1-6 h) and biodistribution were performed in BxPC-3 tumor-bearing mice.
RESULTS: [18F]AlF NOTA-5G was obtained in > 93% radiochemical purity. Cell binding was αvβ6-targeted (1 h: 66% bound to DX3puroβ6, vs 2% to DX3puro), and ≥ 50% of bound activity was internalized; analogous to [68Ga]Ga DOTA-5G, PET imaging showed clearly delineated tumors. Excretion remained primarily renal (1 to 4 h: 18.6 to 12.5% ID/g). Tumor uptake remained relatively steady (1 to 4 h: 2.3 ± 0.4 to 1.8 ± 0.6% ID/g - closely matching [68Ga]Ga DOTA-5G with 2.6 ± 0.8 and 2.0 ± 0.6% ID/g at 1 and 2 h), resulting in tumor/pancreas, tumor/liver, and tumor/blood ratios of 18/1, 24/1, and 162/1, respectively (4 h); by comparison, for [68Ga]Ga DOTA-5G the values were 21/1, 20/1, and 22/1 (2 h).
CONCLUSIONS: [18F]AlF NOTA-5G demonstrated selective αvβ6-targeting and tumor uptake similar to [68Ga]Ga DOTA-5G. The tumor-to-background ratio resulted high-contrast PET images, with an extended imaging window compared to [68Ga]Ga DOTA-5G. The synthesis of [18F]AlF NOTA-5G is currently being optimized for clinical production.
PROCEDURES: NOTA-5G was synthesized on solid phase and radiolabeled with aluminum [18F]fluoride to generate [18F]AlF NOTA-5G. Cell binding and internalization of [18F]AlF NOTA-5G were evaluated in paired DX3puroβ6 (αvβ6 +) and DX3puro (αvβ6 -), and pancreatic BxPC-3 (αvβ6 +) cells. Imaging (1-6 h) and biodistribution were performed in BxPC-3 tumor-bearing mice.
RESULTS: [18F]AlF NOTA-5G was obtained in > 93% radiochemical purity. Cell binding was αvβ6-targeted (1 h: 66% bound to DX3puroβ6, vs 2% to DX3puro), and ≥ 50% of bound activity was internalized; analogous to [68Ga]Ga DOTA-5G, PET imaging showed clearly delineated tumors. Excretion remained primarily renal (1 to 4 h: 18.6 to 12.5% ID/g). Tumor uptake remained relatively steady (1 to 4 h: 2.3 ± 0.4 to 1.8 ± 0.6% ID/g - closely matching [68Ga]Ga DOTA-5G with 2.6 ± 0.8 and 2.0 ± 0.6% ID/g at 1 and 2 h), resulting in tumor/pancreas, tumor/liver, and tumor/blood ratios of 18/1, 24/1, and 162/1, respectively (4 h); by comparison, for [68Ga]Ga DOTA-5G the values were 21/1, 20/1, and 22/1 (2 h).
CONCLUSIONS: [18F]AlF NOTA-5G demonstrated selective αvβ6-targeting and tumor uptake similar to [68Ga]Ga DOTA-5G. The tumor-to-background ratio resulted high-contrast PET images, with an extended imaging window compared to [68Ga]Ga DOTA-5G. The synthesis of [18F]AlF NOTA-5G is currently being optimized for clinical production.